Business Context and Reporting Period
The provided filing is a Form 10-Q for Neuralstem, Inc., not Palisade Bio, Inc. It covers the three months ended March 31, 2015, with comparative results for the three months ended March 31, 2014. Neuralstem develops regenerative-medicine therapies based on human neural stem cells and small-molecule compounds. Its lead programs included NSI-566 and NSI-189, all of which remained in preclinical or clinical development.
Financial Results and Key Metrics
| Metric | Q1 2015 | Q1 2014 | Change |
|---|---|---|---|
| Revenue | $2,917 | $4,167 | Down 30% |
| Research and development expense | $3.18 million | $1.63 million | Up 95% |
| General and administrative expense | $1.43 million | $3.55 million | Down 60% |
| Total operating expenses | $4.62 million | $5.18 million | Down 11% |
| Operating loss | $4.61 million | $5.18 million | Improved $0.56 million |
| Net loss | $5.05 million | $5.92 million | Improved $0.87 million |
| Net loss per share | $0.06 | $0.07 | Improved |
| Net cash used in operating activities | $4.72 million | $2.71 million | Use increased $2.01 million |
Revenue consisted only of licensing fees; the company generated no product-sale revenue. Other expense was $440,165, primarily $453,734 of interest expense, partially offset by interest income. The filing does not present a meaningful operating margin because revenue was negligible and the company remained loss-making.
At March 31, 2015, cash and cash equivalents were $13.59 million and short-term investments were $15.03 million, for approximately $28.63 million of cash and short-term investments. Total assets were $30.80 million, total liabilities were $11.44 million, and stockholders’ equity was $19.36 million. Aggregate long-term debt was approximately $8.88 million on the balance sheet, while management disclosed approximately $9.5 million of aggregate principal outstanding.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased $1.55 million, primarily because of higher project and laboratory costs, payroll, headcount, and travel related to expanded clinical and preclinical activities.
- General and administrative expense declined $2.12 million. The primary driver was a $1.80 million reduction in non-cash stock-based compensation; Q1 2014 included approximately $2.0 million related to a performance-based warrant extension. Legal expense also declined by approximately $466,000.
- Net loss improved by $866,000 despite substantially higher research and development spending.
- Operating cash use increased 74% to $4.72 million, reflecting the higher operating costs and working-capital changes.
- Investing cash use declined sharply because Q1 2015 included a short-term investment maturity that largely offset new purchases, whereas Q1 2014 included approximately $15.0 million of net investment purchases.
- Financing cash inflow declined to $5.89 million from $19.43 million. Q1 2015 financing included $2.93 million from At-the-Market share sales and $3.07 million from warrant exercises.
- Shares outstanding increased to 90.34 million at March 31, 2015 from 87.79 million at December 31, 2014. Approximately 42.7 million additional shares were reserved for equity awards and outstanding options, warrants, and convertible securities.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management stated that available cash and expected income were expected to fund current activities at least through March 31, 2016, but also stated that long-term cash resources were inadequate to fund the full range of required testing and clinical trials.
- The company expected research and development spending to increase as additional Phase II trials proceeded. Planned 2015 activities included a controlled Phase II ALS study, a Phase II stroke trial, a Phase II NSI-189 depression trial, and a Phase Ib schizophrenia trial.
- The company did not expect to be profitable in the next several years and anticipated additional operating losses. Additional financing would be required for clinical development, manufacturing, regulatory activities, and working capital.
- The amended debt facility totaled $10 million, carried a variable interest rate with a 10% floor, and required interest-only payments through September 2015, approximately $461,000 of monthly principal and interest payments from October 2015 through March 2017, and an approximately $2.1 million balloon payment in April 2017. Substantially all assets, including intellectual property, secured the debt.
- Principal risks included clinical-trial failure or delay, regulatory non-approval, dependence on third-party manufacturers and clinical research organizations, intellectual-property disputes, future financing needs, dilution, debt-service obligations, and lack of commercial product revenue.
- Neuralstem was involved in long-running patent litigation with StemCells, Inc. A bench trial concerning standing and inventorship occurred in December 2014, and the court’s subsequent order could either resolve the case or permit further expert discovery. Management believed the litigation would not have a material adverse effect, but the outcome and timing were uncertain.
- The company planned to bring some spinal-cord stem-cell manufacturing in-house and expected the relocated facility to be ready for clinical-trial manufacturing by the second quarter of 2015.
- On May 5, 2015, the company announced the appointment of Jonathan Lloyd Jones as CFO, effective May 18, 2015.
Most Important Facts for an Investor to Verify
- Confirm the issuer identity: the supplied filing is for Neuralstem, Inc., whereas the request metadata identifies Palisade Bio, Inc.
- Verify the company’s cash runway and the likelihood, timing, and terms of additional equity or debt financing.
- Review debt covenants, required payments beginning October 2015, and the April 2017 balloon payment.
- Assess clinical-trial enrollment, safety and efficacy data, regulatory milestones, and whether the stated 2015 development plans were achieved.
- Evaluate dilution from outstanding options, warrants, reserved shares, and future capital raises.
- Monitor the StemCells patent litigation and any effect on the company’s intellectual-property portfolio or clinical programs.
- Verify manufacturing readiness, regulatory compliance, and reliance on Charles River Laboratories, AMRI, and other third parties.